Tislelizumab 是一种对PD-1受体具有高结合亲和力的单克隆抗体，可最大限度地减少 Fcγ 受体与巨噬细胞的结合，从而消除抗体依赖性吞噬作用，这是一种 T 细胞清除机制，可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。
| 生物活性 | Tislelizumab, a monoclonal antibody with high binding affinity to thePD-1receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lungcancer[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
